E. Werner, Maria C B van Hooff, Gemma Weijsters, Maria A. van de Vrie, Rozanne C. de Veer, U. Beuers, Joost P.H. Drenth, Frans J.C. Cuperus, Remco van Dijk, Bart J. Veldt, Michael Klemt‐Kropp, Suzanne van Meer, Robert C. Verdonk, Hajo J. Flink, Jan Maarten Vrolijk, Matthijs Kramer, Cyriel Y. Ponsioen, Kirsten Boonstra, Femke Boersma, Hendrik J.M. de Jonge, Frank H.J. Wolfhagen, L.C. Baak, Susanne L. Onderwater, Jeroen D. van Bergeijk, Paul G. van Putten, G.J. de Bruin, Rob P. R. Adang, Maria N. Aparicio‐Pages, Wink de Boer, Frank ter Borg, Hanneke van Soest, E de Vries, Nicole S. Erler, Bettina E. Hansen, H Janssen, Adriaan van der Meer, the Dutch PBC Study Group
BACKGROUND: Optimal care delivery for primary biliary cholangitis (PBC) has become challenging due to new therapies and more individualized biochemical treatment goals. AIM: To evaluate uptake of ursodeoxycholic acid (UDCA) and second-line therapy (SLT) in a nationwide PBC cohort and identify factors associated with suboptimal therapeutical management. METHODS: The Dutch PBC Cohort Study is a retrospective study including every identifiable patient with PBC in the Netherlands from 1990 onwards. Use of UDCA and SLT was assessed among patients in clinical follow-up on 1 January 2019. Biochemical response was defined as alkaline phosphatase (ALP) and aspartate aminotransferase (AST) ≤ 1.5 × ULN and total bilirubin (TB) ≤ ULN. SLT included off-label fibrates, budesonide and/or obeticholic acid (not reimbursed). RESULTS: In total, 2638 patients with PBC were included; median age was 64.0 (IQR 55.0-72.0) years, 2361 (89.5%) were female and 2143 (81.2%) were treated in a non-academic center. Overall, 2532 (96.0%) patients used UDCA. The recommended UDCA dose of ≥ 13 mg/kg/day was used by 1363/2205 (61.8%). Age (aOR 1.01, 95% CI 1.00-1.02, p = 0.02), body weight (aOR 1.04, 95% CI 1.03-1.05, p < 0.01) and biochemical response (aOR 1.35, 95% CI 1.09-1.67, p = 0.01) were associated with UDCA dosage < 13 mg/kg/day. Among patients with an incomplete response, 101/638 (15.8%) were prescribed SLT. Younger age, female sex, treatment in an academic centre and higher levels of ALP and AST were positively associated with use of SLT. CONCLUSIONS: During recent years, UDCA was insufficiently dosed in Dutch patients with PBC. The results indicate that first-line treatment can be optimized, especially in those with a biochemical response and higher body weight.